| Range: | 6.63-12.378 | Vol Avg: | 188178 | Last Div: | 0 | Changes: | -0.08 |
| Beta: | 0.33 | Cap: | 0.44B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Oct 29 2021 | Empoloyees: | 88 | ||
| CUSIP: | 05153U107 | CIK: | 0001501796 | ISIN: | US05153U1079 | Country: | US |
| CEO: | Dr. Elisabet de los Pinos Ph.D. | Website: | https://www.aurabiosciences.com | ||||
AURA 8.95 Stock Price Aura Biosciences, Inc.
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow